Background Information on Pathelen® Hybrid

How it works

The PATHELEN® HYBRID WOUND CARE TREATMENT (PWCT) is based on a medical device, which has been specifically designed and developed for the treatment of multi resistant bacteria (such as MRSA) in open wounds. PWCT generally eliminates most external bacterial wound infections within 5-10 days prepare the treated wound for a wound closure surgery or /and enhance the growth of granulating tissue on the treated wound. The effect of Pathelen® Hybrid treatment is based on the physical adsorption of wound exudate and biofilm. In a bottle with 2g Pathelen Hybrid the particle surface is 600qm.

The invention of PATHELEN® Hybrid relates to new compositions based on synthetic highly dispersed silicas that have high adsorptive abilities that can be used in different fields of practical medicine for the treatment of diseases which are caused by pathogenic microorganisms, in particular, purulent wounds.

Clinical practice shows that the treatment of chronical inflammatory diseases and purulent wounds by using modern antimicrobial agents only, does not reach the desired result.

Misuse of antibiotics contributes to the emergence of resistant (hospital) strains of pathogenic microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA) and other multi resistant bugs, which is a serious challenge for modern medicine in general.

The intensity of the regeneration process and healing of infected ulcers and wounds depends largely on the speed at which they are cleared from the biofilm, pus and necrotic tissues.

Applique adsorption is a kind of physically adsorption detoxification which after the Pathelen Hybrid treatment accelerates wound healing and restores the integrity of the skin and mucous membranes by the removal of microbial cells, bacterial toxins and toxic metabolites of wound fluid and wound cavities in direct contact with the surface of the adsorptive preparation.
An important therapeutic factor in the first phase of wound healing is also seen in the dehydration, i.e., adsorption of fluid from the wound cavity and perifocal tissues.

Pathelen® Hybrid can be used in the first phase of wound healing.

Its detoxifying action is due to the ability to adsorb pathogenic protein substances (up to 800 mg/g), including microbial enzymes, exo- and endotoxins (Lipopolysaccharides) and microorganisms.



The surface of the silica is covered with hydroxyl groups that can bind water molecules, so it produces a pronounced dehydrating effect on the tissue that is essential for the removal of edema as part of the inflammatory process.

However, silica, due to lack of porous structure, does not adsorb low and middle molecular weight toxic metabolites.

Pathelen® Hybrid does not show direct antimicrobial action; however, it was found that the sensitivity of pathogenic organisms to antibiotics is increased in the presence of.

Noteworthy is a combination of hydrophilic and hydrophobic sorbents, providing sorption of a wide range of substances and pathogenic microorganisms in wounds. Through a combination of hydrophilic and hydrophobic sorbents these products can provide clean wounds through a selective sorption and draining effect.

The aim of the invention PATHELEN® Hybrid has been to create an universal hydrophilic- hydrophobic composition having an adsorptive and detoxifying effect for the treatment of purulent wounds and other purulent-inflammatory diseases such as chronic purulent-granulomatous inflammation, purulent-necrotic inflammation.

The composition of PATHELEN® Hybrid according to this invention may be varied, depending on the phase of wound healing. This may be achieved by varying the dehydrating ability, adding compounds having a wide range of antimicrobial activity, including against aerobic and anaerobic microorganisms. Moreover, additional compounds may be added which exhibit necrolytic effects on non-vital tissues, enhance the regenerative effect on the young tissue and/or provide a local anesthetic effect.

By using the composition of PATHELEN® Hybrid according to the present invention, a more effective treatment of wounds of different nature in various stages of wound healing may be achieved, which include: exudating wounds, chronic pressure ulcers, venous leg ulcers, diabetic/neuropathic ulcers, fungating, cancerous or malignant lesions and wounds with necrotic tissue.